This website is owned and developed by Boehringer Ingelheim and contains promotional information.
This website is intended for UK and Ireland Healthcare Professionals only. If you are not a Healthcare Professional in the UK or Ireland please click here.
Click here for OFEV® (nintedanib) UK prescribing information. Find adverse event reporting information at the bottom of this page.
Click here for OFEV® (nintedanib) Ireland prescribing information. Find adverse event reporting information at the bottom of this page.

Accessibility Statement

Accessibility Statement for Boehringer Ingelheim websites

Boehringer Ingelheim is committed to providing a website that is accessible to the widest possible audience, regardless of technology or ability. We are actively working to increase the accessibility and usability of our website and in doing so adhere to many of the available standards and guidelines. These guidelines explain how to make web content more accessible for people with disabilities. Conformance with these guidelines will help make the web more user friendly for all people. We are continually seeking out solutions that will bring all areas of the Site up to the same level of overall web accessibility.

Access Keys

Hot Keys provide short cuts to certain pages within the web Site. To use the access keys hold down the ‘Alt’ key and enter the ‘Hot key’ number. The following shortcut Hot keys are active on the Boehringer Ingelheim website:

  • 0- Accessibility page

  • 1- Homepage

  • 2- Site Map

  • 3- Search

  • 4- Contact

  • 5- Print

  • 6- Skip Navigation

Multimedia elements: Images, video and audio files

Alternative and short descriptive texts are available for all multimedia and non-text content. A simplified version of the Site is also available, displaying a page with descriptive texts in the place of all images and videos. All videos and multimedia give a size indication, so that downloading time can be estimated. If software is required to view the videos, a plug in download link will be posted. An HTML substitute for Flash Player will also be provided for future videos. All videos will be presented with player software which enables the user to play, pause, stop forward and rewind the video. Live web casts will be archived after broadcasting to be available for a later viewing. No flashing content will be provided.

Presentation of Content and Layout

There is a strict separation of content and layout via the proper use of HTML and CSS (Cascading Style Sheet). Layout tables are avoided where possible.

We are focusing on structuring items, making it possible to scan through a document and giving air to long texts. This includes:

  • chapter starting pages that show which content is provided within subchapters

  • consequent use of headlines, short introduction text on every webpage and sub headlines

  • tables and bullet list for helping readers

  • graphics for complex content.

We try to offer a clear navigation structure that helps you to find the content you are looking for in an easy and quick way.

Links contain title attributes which describe content and make sense out of context.

The use of short sentences and paragraphs and multiple entry points to additional information sources e.g. via teaser elements and related content areas will make it easier to comprehend the content.

In the meantime, should you experience any difficulty in accessing the Boehringer Ingelheim website, please do not hesitate to contact us.


Adverse events should be reported.

UK: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) or by email to PV_local_uk_ireland@boehringer-ingelheim.com.

IE: Reporting forms and information can be found at www.hpra.ie/homepage/about-us/report-an-issue. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 01 291 3960 or by email to PV_local_uk_ireland@boehringer-ingelheim.com.

OFEV® is indicated in adults for the treatment of idiopathic pulmonary fibrosis (IPF) and for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. The recommended dose is one 150 mg capsule taken twice daily.1